Research Report: CERITER Clinical Study - Stride One
Launched by CERITER NEDERLAND BV · Aug 16, 2024
Trial Information
Current as of August 02, 2025
Completed
Keywords
ClinConnect Summary
Both therapist and patient reported an improvement in the quality of the foot roll-off pattern in 100% of cases. This improvement was also objectively determined in the data measured by Stride One, with an average of 8% improvement on Stride One general quality parameter, and an average of 25% improvement on Stride One specific quality parameter for the specific patient. Furthermore, 89% of patients indicate that using Stride One helps them to understand their physiotherapist better, and 67% of patients indicate that they can practice more and better with Stride One.
Practicing one week wi...
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • CVA, residentially admitted to the rehabilitation center in Herk-de-Stad, Belgium
- • Older than 18 years of age
- • Gait problems as a result of the CVA
- • Able to walk safely and independently (possibly with a walking aid)
- • Able to understand and sign an information and consent form
- Exclusion Criteria:
- • Severe cognitive problems (attention) that make it difficult to understand instructions or follow feedback
- • Hearing problem
About Ceriter Nederland Bv
Ceriter Nederland BV is a forward-thinking clinical trial sponsor dedicated to advancing medical research and innovation. With a strong emphasis on patient safety and ethical standards, Ceriter collaborates with healthcare professionals and research institutions to design and execute clinical trials that drive the development of new therapies and treatment strategies. Leveraging a robust network and expertise in regulatory compliance, Ceriter ensures the efficient management of trial processes, facilitating valuable insights that contribute to the enhancement of patient care and outcomes.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Hasselt, , Belgium
Patients applied
Trial Officials
Sarah Meyer
Study Director
Frame Jessa Ziekenhuis
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported